Brand Intelligence Graph
Company Overview
About Timberlyne Therapeutics
Timberlyne Therapeutics launched in January 2025 with $180 million in Series A financing from Abingworth, Bain Capital Life Sciences, and Venrock, developing CM313 — an anti-CD38 monoclonal antibody with differentiated complement-dependent cytotoxicity properties. CM313 achieved a 95% response rate in treatment-refractory immune thrombocytopenia (ITP) in data published in the New England Journal of Medicine in 2025 — a 95% response rate in refractory patients is exceptional in autoimmune disease.
Business Model & Competitive Advantage
CD38 is a cell surface protein highly expressed on plasma cells that produce pathogenic antibodies in multiple autoimmune conditions. Existing anti-CD38 drugs (daratumumab, isatuximab) are approved for multiple myeloma but have different cytotoxicity mechanisms than CM313. Timberlyne's complement-dependent cytotoxicity approach may provide more complete plasma cell depletion in autoimmune settings where existing anti-CD38 drugs have shown incomplete responses.
Competitive Landscape 2025–2026
In 2026, Timberlyne is advancing CM313 across multiple autoimmune indications beyond ITP, leveraging the NEJM data as a clinical proof-of-concept for the CD38 target in autoimmunity more broadly. The combination of high-quality clinical data in a prestigious journal and a multi-indication expansion strategy positions Timberlyne for significant 2026-2027 clinical milestones.
Key Differentiators
Emerging Innovator
Timberlyne Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Timberlyne Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Timberlyne Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Timberlyne Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Timberlyne Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →